Sunlight GLP-1 2026: Compounded Semaglutide From $159, What FDA's June 2026 Decision Means for Compounded GLP-1 Buyers, and 9 Things to Verify Before You Enroll

KIRKLAND, Wash., May 28, 2026 (Newswire.com) - Disclosure: This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products or services. Disclosure is provided in accordance with FTC 16 CFR Part 255. This content is promotional in nature and is intended for consumer education regarding a commercially available telehealth service. This content was prepared with editorial and AI-assisted drafting support. All claims were reviewed against available brand, regulatory, and legal source materials before publication.

Title Reference Notice: This article's title uses "GLP-1" as the scientific category descriptor for the drug class Sunlight.com facilitates access to. The price reference ("From $159") reflects Sunlight's brand-published starting price per its FAQ - buyers should confirm at checkout. "FDA's June 2026 Decision" refers to the FDA's April 30, 2026 proposal - published in the Federal Register (91 Fed. Reg. 23431, May 1, 2026) and sourced in this article from fda.gov - to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facilities bulk drug substances list, with a public comment period open through the end of June 2026. "9 Things to Verify" refers to the buyer verification checklist in this article. "FDA Safety Warnings" refers to published FDA guidance on compounded GLP-1 medications. None of this constitutes an endorsement of Sunlight or a recommendation by this publication.

Sunlight GLP-1 is a telehealth platform operated by GLP-1, LLC d/b/a Sunlight.com, LLC (Kirkland, WA) that connects patients with licensed clinicians for compounded semaglutide (starting at $159/month) and tirzepatide (starting at $239/month). The program includes unlimited telehealth visits, free 2-day shipping, and requires no insurance. Sunlight reports 100,000+ patients served, based on self-reported data. Compounded GLP-1 medications are not FDA-approved. On April 30, 2026, the FDA announced a formal proposal - published in the Federal Register - to exclude semaglutide and tirzepatide from the 503B outsourcing compounding list, with a public comment period open through the end of June 2026. If that proposal becomes final, large-scale compounded GLP-1 availability changes significantly. Whether Sunlight is right for you, and whether now is the right time to start, depends on factors this guide covers in full.

Sunlight GLP-1 2026: Fast Facts Every Buyer Should Know in 30 Seconds

• Platform operator: GLP-1, LLC d/b/a Sunlight.com, LLC - 11335 NE 122nd Way, Suite 105, Kirkland, WA 98034

• Platform type: Telehealth technology platform - not a medical provider; connects patients with licensed clinicians via affiliated Medical Groups (OpenLoop Health, JMP Medical)

• Medications offered: Compounded semaglutide and compounded tirzepatide, per Sunlight's published materials. Compounded medications are not FDA-approved and are not identical, interchangeable, or equivalent to FDA-approved branded products. The FDA has specifically warned that some compounded semaglutide products have used semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) that differ from the active ingredient in FDA-approved medications - buyers should ask Sunlight to confirm the specific form used

• FDA status: Compounded versions not FDA-approved for safety, quality, or efficacy - Sunlight's own terms state this explicitly

• Compounding pharmacy model: Per Sunlight's Terms of Use, its partner pharmacies fill patient-specific prescriptions from licensed clinicians - distinct from large-scale outsourcing facilities. The FDA is reviewing large-scale outsourcing compounding of these drugs and has tightened enforcement after the drug shortages were resolved

• Starting price: Semaglutide from $159/month; tirzepatide from $239/month (first month pricing; subscription service)

• Included: Prescription (if approved), unlimited telehealth visits, free 2-day shipping, 4-week supply per shipment

• Insurance: Not required. Sunlight describes its GLP-1 plans as self-pay with flat monthly pricing; HSA/FSA payments accepted. Confirm payment options at checkout

• Pharmacy partners: RedRock Pharmacy (St. George, UT), Health Warehouse (Florence, KY), Precision Compounding Pharmacy (Bellmore, NY), Triad Rx (Daphne, AL)

• Medical team: Angela Tran, D.O. (Chief Medical Advisor, dual board-certified Obesity Medicine/Internal Medicine); Ilya Rabkin, MD, MBA, FAAFP; Amanda Simone-Belin, MD

• Availability: All 50 states plus Washington D.C. (per brand; subject to state-specific clinical eligibility)

• Cancellation: Cancel anytime by emailing [email protected]; subscription auto-renews

• Refund policy: Once a prescription (first or refill) is written and sent to pharmacy, no refund available; medically disqualified patients receive refund for unused months

• LegitScript: Brand states LegitScript-certified telehealth platform

• Patient count (brand-reported): 100,000+ - based on self-reported data, not independently audited

• Reported outcomes (brand-reported, self-reported data): Sunlight states on its website: "On average, patients lose more than 20 pounds in just 3 months"; "90% of patients report losing weight in the first month"; "4 in 5 patients say GLP-1 is the most effective weight loss method they've tried"; "60% of patients report dropping 2 or more clothing sizes." Per Sunlight's own disclosure: results may vary depending on adherence and provider guidance. These figures are brand-reported and not independently verified by this publication

• Delivery timeline: Ships within 7 business days of approval; tracking provided by email and text

• Contact: [email protected] | 1-877-378-7008

• Governing law: State of Iowa; Polk County District Court, Des Moines

• FDA June 2026 deadline: The FDA's public comment period on its proposal to exclude semaglutide and tirzepatide from the 503B outsourcing compounding list closes at the end of June 2026 (per fda.gov). If finalized, large-scale bulk compounding of these medications ends. Sunlight's patient-specific prescription model is a separate pathway - but buyers should verify current program status before enrolling

• As of: May 2026 - FDA regulatory environment for compounded GLP-1 is actively evolving; verify current status at Sunlight.com before enrolling

View the current Sunlight GLP-1 offer (official Sunlight page)

Buyer Takeaway: Sunlight is a technology platform - not a clinic. It connects you with licensed clinicians who independently decide whether to prescribe. The underlying drug class - GLP-1 receptor agonists - has substantial clinical trial evidence for FDA-approved branded formulations; compounded versions are not FDA-approved and carry a distinct regulatory status from brand-name versions. That distinction matters in 2026 more than it did in 2023.

About the Promotional Language on Sunlight's Website

If you arrived at this article from a Sunlight advertisement or landing page, you've probably seen phrases like "100,000 happy customers," "98% patient success rate," "lose 20% of your body weight," and "the medication that's changing weight loss." This section explains what each of those phrases means in the context of how they're sourced - and what they don't mean - so you can read the rest of this article with the right frame.

• "100,000+ happy customers" / "trusted by 100k+ Americans" - Source: Sunlight's official website and marketing materials. What it means: Sunlight reports having served more than 100,000 patients. What it doesn't mean: This figure hasn't been audited by this publication or any independent third party named on Sunlight's site. Customer ratings and self-reported data are the basis for this figure, per Sunlight's own disclaimers.

• "98% patient success rate" - Source: Sunlight's official website. What it means: Sunlight reports this figure from its own patient data. What it doesn't mean: This publication has not independently verified this figure. Per Sunlight's own footer: "All claims and benefits referenced are based on self-reported data from Sunlight users following a treatment plan with compounded GLP-1 medications and medical consultations. Results may vary depending on adherence to the program and provider guidance."

• "Lose 20% of your body weight" / "15-20% body weight loss" - Source: Sunlight's website, attributed to average patient outcomes per brand-reported data. What it means: This aligns with clinical data for FDA-approved semaglutide (Wegovy) and tirzepatide (Zepbound) from peer-reviewed trials - not from compounded versions specifically. The SUSTAIN and SURMOUNT trial programs for branded drugs showed 15-20% weight reduction in study populations over 68-72 weeks. Sunlight attributes this figure to its own patient program. What it doesn't mean: Individual results vary widely. Not every patient achieves this outcome. This publication doesn't represent this figure as a guarantee.

• "The medication that's changing weight loss" - Source: Sunlight's official website. What it means: A reference to the documented category shift GLP-1 receptor agonists have created in clinical weight management - a scientifically supported statement about the drug class. What it doesn't mean: It's Sunlight's marketing positioning, not an independent editorial endorsement by this publication.

• "LegitScript-certified" - Source: Sunlight's official website. What it means: LegitScript is a compliance organization that certifies online pharmacies and telehealth platforms that meet its verification standards. This certification is verifiable at legitscript.com. What it doesn't mean: LegitScript certification doesn't substitute for FDA approval of the specific compounded products dispensed.

Buyer Takeaway: Sunlight's promotional statistics are brand-reported and rooted in self-reported patient data - which is standard for telehealth platforms at this stage. The clinical science behind GLP-1 receptor agonists as a drug class is separately and independently robust. These two things are different, and understanding the difference is what makes you an informed buyer.

Is Sunlight GLP-1 Legit? What the Verification Checklist Turns Up

The quickest way to answer "is Sunlight legitimate" is to check the things that separate real telehealth platforms from questionable ones. Here's what the verification framework finds:

Sunlight is operated by a named legal entity - GLP-1, LLC d/b/a Sunlight.com, LLC - with a published physical address in Kirkland, Washington, a published phone number (1-877-378-7008), and a published support email ([email protected]). The governing law clause in its Terms of Use names Iowa as the jurisdiction, and the Terms were last updated in April 2026, which confirms active maintenance of legal documentation. A telehealth platform that's not real doesn't have active terms of use naming specific courts and jurisdictions.

Sunlight lists the following care team members in its published materials, with stated credentials. Dr. Angela Tran, D.O. is listed as Chief Medical Advisor and the brand describes her as double-board-certified in Obesity Medicine and Internal Medicine with 10+ years of clinical experience. Board certifications in those specialties are verifiable through ABIM (American Board of Internal Medicine) and ABOM (American Board of Obesity Medicine). Dr. Ilya Rabkin, MD, MBA, FAAFP is listed as board-certified in Family Medicine, with Gold Humanism Honor Society recognition - also verifiable. Dr. Amanda Simone-Belin, MD is listed as board-certified in Internal Medicine with a specialty in medical weight loss. Having named, verifiable clinicians with published credentials is a material legitimacy indicator.

The pharmacy partners are named entities with published addresses. RedRock Pharmacy is in St. George, Utah. Health Warehouse is in Florence, Kentucky. Precision Compounding Pharmacy is in Bellmore, New York. Triad Rx is in Daphne, Alabama. Sunlight's Terms of Use list all four as pharmacy partners. You can verify pharmacy licenses through state pharmacy board public registries.

Sunlight's own legal documents acknowledge the limitations of its service clearly: prescriptions aren't guaranteed, compounded GLP-1s aren't FDA-approved, and the platform is a technology connector - not a medical provider. A platform that discloses these limitations explicitly is doing more than the minimum legally required.

The LegitScript certification Sunlight claims is verifiable at legitscript.com. LegitScript's certification process for telehealth platforms reviews prescriber licensing, pharmacy sourcing, and compliance with applicable law.

Buyer Takeaway: Sunlight's published materials provide several transparency signals, including a named legal operator, contact information, telehealth consent terms, clinician-review language, and listed pharmacy partners. Named operator, verifiable address, named credentialed physicians, named licensed pharmacy partners, up-to-date legal terms, and LegitScript certification are all present. The legitimacy question that deserves more depth is the regulatory status of the compounded medications - which the next section covers.

What Every Compounded GLP-1 Buyer Needs to Know Right Now - and Why the June 2026 FDA Deadline Changes the Calculation

This is the section that separates informed buyers from people who just trust the landing page. If you're considering any compounded GLP-1 program - not just Sunlight - you need to understand what changed with FDA compounding regulation, why it changed, and what that means for your enrollment decision right now.

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) became widely available through compounding pharmacies because the FDA placed them on its drug shortage list starting in 2022. When a drug is on the shortage list, compounding pharmacies can legally prepare copies of it to meet demand that approved manufacturers can't satisfy. That exception created a large and fast-growing compounded GLP-1 market - with programs priced at $150-$300 per month versus $1,000+ for brand-name alternatives.

That exception is now significantly restricted. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, with enforcement deadlines that have now passed for both. After the FDA determined that these shortages were resolved, the enforcement framework for compounded GLP-1 medications changed significantly.

On April 30, 2026, the FDA announced a formal proposal, published in the Federal Register (91 Fed. Reg. 23431, May 1, 2026), to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facilities bulk drug substances list - finding no clinical need for large-scale outsourcing facilities to compound these medications when FDA-approved supply is commercially available. The public comment period on this proposal is open through the end of June 2026 at regulations.gov. FDA Commissioner Marty Makary stated: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." If the proposal is finalized, it closes the primary remaining pathway for large-scale compounded GLP-1 production in the United States. Industry analysts, including those at Pharmacy Times and major healthcare law firms, expect a final rule in late summer 2026. For buyers researching Sunlight right now: the FDA comment deadline is weeks away. Verify current program availability directly with Sunlight before enrolling.

Large-scale "essentially a copy" compounding of these drugs lost its legal basis once the shortage pathway closed. The FDA has continued to strengthen enforcement and has issued formal guidance signaling that the compounded GLP-1 category is under ongoing regulatory scrutiny.

The FDA has also warned consumers directly about risks associated with unapproved GLP-1 products and compounded versions. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses - some of which required hospitalization. The FDA has also flagged concerns about counterfeit GLP-1 products, fraudulent labeling, and - critically - semaglutide salt forms. Some compounded products have used semaglutide sodium or semaglutide acetate rather than the active ingredient in FDA-approved semaglutide. These salt forms are not the same compound. Buyers should specifically ask any compounded GLP-1 provider to confirm what form of the active ingredient is used and from which pharmacy.

The practical question for Sunlight specifically: its partner pharmacies fill patient-specific prescriptions from licensed clinicians. Patient-specific compounding under a licensed prescriber's order operates under different legal authority than large-scale outsourcing. But the legal framework for this category remains under active regulatory review, and availability can change. Buyers should verify current compounding status directly with Sunlight at [email protected] or 1-877-378-7008 before enrolling.

The clinical science supporting FDA-approved GLP-1 receptor agonists as a drug class is separately strong and not in dispute. FDA-approved semaglutide (Wegovy) and tirzepatide (Zepbound) have substantial clinical trial evidence for chronic weight management in appropriate patients. The question specific to compounded versions isn't whether GLP-1 drugs work - the FDA-approved data supports that conclusion - it's whether the specific compounded version you're receiving matches the compound studied, and whether it's available under current regulatory conditions.

Buyer Takeaway: The regulatory framework for compounded GLP-1 medications changed materially in 2024-2025 and is still evolving. Sunlight's program operates under a patient-specific prescription model through state-licensed partner pharmacies. Before enrolling, confirm current availability, verify the specific compounded form used, and ask directly whether the program is currently operating within FDA enforcement guidance.

View the current Sunlight GLP-1 offer (official Sunlight page)

How Does Sunlight GLP-1 Work? The Full Process From Quiz to Delivery

Sunlight's enrollment process moves through four stages, and the timing of each one matters - especially because the refund cutoff is tied to when your prescription gets written, not when your medication arrives.

You begin with a health intake quiz on Sunlight's website. This isn't a casual questionnaire - it collects medical history, current medications, existing health conditions, and your weight loss goals. The information goes to a licensed clinician affiliated with Sunlight's Medical Group partners (OpenLoop Health or JMP Medical). The clinician reviews your intake and determines whether a telehealth appointment is needed or whether they can evaluate your case asynchronously.

If you're approved, a prescription is written for either compounded semaglutide or tirzepatide based on the clinician's independent medical judgment. "Independent judgment" here is legally meaningful - Sunlight's terms explicitly state that GLP-1, LLC d/b/a Sunlight.com, LLC does not control or interfere with the prescribing decisions of its affiliated clinicians. You might complete the intake quiz and be found ineligible for prescription - that's the clinician's call, not Sunlight's platform.

Prescriptions are shipped to the address you provide within 7 business days of approval. You'll get tracking information via email and text. Each shipment contains a 4-week supply of medication. The medications are prepared by one of Sunlight's four pharmacy partners based on your prescription.

Ongoing support is included at no additional cost. If you hit a plateau, have questions about administration, or need a dosage adjustment, the clinical team handles that through the platform. Per Sunlight's FAQ, dose adjustments are part of the included care - not a separate charge. You'll complete a refill form after your third weekly dose to keep your supply uninterrupted.

Injection and oral options are available, according to the brand's website, though the specific oral formulations available depend on your clinical evaluation. The lander references both injections and oral options.

Buyer Takeaway: The process is genuinely 100% online - there's no in-person visit. The prescription decision belongs to the licensed clinician, not the platform. Approval isn't guaranteed, which is how a legitimate telehealth service operates.

Sunlight GLP-1 Pricing: What You Actually Pay

The pricing structure Sunlight discloses on its website is straightforward compared to some telehealth platforms in this category, but there are nuances worth understanding before you enroll.

Semaglutide starts at $159 per month. Tirzepatide starts at $239 per month. These are brand-stated starting prices for the first month. According to Sunlight's FAQ, the flat monthly rate includes the prescription (if approved), unlimited telehealth visits, and free shipping. There are no hidden fees, no monthly membership fees separate from the medication cost, and no insurance requirement.

These prices are substantially lower than brand-name equivalents. Ozempic and Wegovy have retail list prices that typically exceed $1,000 per month without insurance. The patient testimonial on Sunlight's site describes paying over $1,200 per month at a previous provider for tirzepatide. Sunlight's pricing is brand-stated as covering the active compounded medication - the cost difference versus branded products reflects both the compounding model and the telehealth delivery structure.

This is a subscription service. Your payment method is automatically charged at regular monthly intervals as described during checkout. You can cancel anytime by emailing [email protected]. Cancellation stops future charges; you retain access through the end of your current billing period. Per Sunlight's Terms of Use, subscription fees are not refundable once incurred, with the exception that medically disqualified patients receive refunds for unused months.

The refund restriction that matters most: once a prescription - first or refill - is written and sent to the pharmacy for fulfillment, no refund is available for that order, because the pharmacy fulfillment process is triggered and those costs aren't recoverable by the time the medication is prepared and shipped. You should not begin the enrollment process if you're uncertain about commitment, because the prescription being written triggers the point of no return for that billing cycle, and unlike subscription services for content or software where you can cancel and receive a prorated refund, a prescription-based telehealth service has a hard cutoff tied to the prescribing event rather than the delivery event.

Pricing confirmed at checkout reflects the final total. Shipping is free per brand statements. Tax treatment depends on your jurisdiction. Confirm your complete total at checkout before completing your purchase - pricing stated in this article reflects brand-published information as of May 2026 and may change without notice.

HSA and FSA payments are accepted. All major credit cards are accepted.

Buyer Takeaway: Sunlight's pricing model is among the more transparent in the compounded GLP-1 telehealth space - flat monthly rate, no hidden fees, free shipping disclosed upfront. The subscription and refund structure requires careful reading before enrolling.

View the current Sunlight GLP-1 offer (official Sunlight page)

What Sunlight Includes vs. What's Not Included

The "what's included" question is where some telehealth GLP-1 programs create confusion. Sunlight's disclosures on this are explicit - but reading them carefully still matters.

Included in the monthly subscription: the compounded GLP-1 prescription (if clinically approved), unlimited video visits with licensed clinicians, dosage adjustment consultations, ongoing patient support, and free 2-day shipping on each monthly supply. There's no separate "consultation fee" layered on top - these are all included in the flat monthly rate, per brand statements.

Not included: any services provided by outside companies. Sunlight's Terms state that lab services, pathology, radiology, and other healthcare services not provided by the affiliated Medical Groups or Partner Pharmacies are billed separately by those companies. If a clinician recommends you get bloodwork done, that's separate. If a specialized diagnostic is ordered, that's separate.

Not included: in-person services. The entire program operates via telehealth. Per the Telehealth Consent Form, clinicians acknowledge they can't conduct physical examinations, which could limit their ability to assess certain conditions. If your situation requires in-person care, the platform will tell you that - and you should expect to be redirected.

Not guaranteed: a prescription. A clinician reviews every intake and makes an independent prescribing decision. The enrollment process includes a medical eligibility evaluation, and not every applicant will be prescribed.

Not included (important for California patients specifically): Sunlight's Services currently operate in all 50 states plus D.C. but California patients have additional rights under state law, including access to the Open Payments database for physician payment transparency. See the California-specific disclosures in Sunlight's Telehealth Consent Form.

Buyer Takeaway: The flat monthly rate covers more than most people expect from a telehealth service - unlimited clinician contact is genuinely included. The limits are the same as any telehealth model: no in-person exam, no guarantee of prescription, and ancillary services outside the platform are billed separately.

Sunlight GLP-1 vs. Ozempic, Wegovy, Mounjaro, and Zepbound: Regulatory Differences Buyers Should Understand

This comparison matters more in 2026 than it did two years ago. The "compounded vs. brand-name" question has moved from a cost discussion to a regulatory and clinical discussion.

Sunlight states that its program involves compounded semaglutide and compounded tirzepatide. Compounded medications are not FDA-approved and should not be described as identical, interchangeable, or equivalent to FDA-approved branded products. An important caveat: the FDA has specifically warned that some compounded semaglutide products have used semaglutide salt forms - such as semaglutide sodium or semaglutide acetate - that are not the same as the active ingredient in FDA-approved medications. Buyers should ask any compounded GLP-1 provider specifically what form is being used. The branded reference medications in this drug class are Ozempic and Wegovy (semaglutide, Novo Nordisk) and Mounjaro and Zepbound (tirzepatide, Eli Lilly). Both classes are GLP-1 receptor agonists - they work by mimicking the glucagon-like peptide-1 hormone, slowing gastric emptying, influencing appetite signaling in the brain, and supporting glucose regulation.

The regulatory status is different. FDA-approved brand-name versions have passed the FDA's premarket review for safety, efficacy, and quality. Compounded versions have not. Sunlight's own Terms and its partner pharmacies' documentation acknowledge this explicitly. FDA enforcement actions after the shortage resolutions reflect the FDA's position that the clinical need for large-scale compounded versions no longer exists now that brand-name supplies are stable.

The quality control infrastructure is different. Brand-name manufacturers operate under FDA's cGMP (current Good Manufacturing Practice) standards with continuous federal oversight. Compounding pharmacies operate under state pharmacy board oversight for 503A facilities and FDA oversight for 503B. Both frameworks have standards - they're different standards with different enforcement structures.

The cost is different. Brand-name GLP-1 medications without insurance coverage can exceed $1,000 per month. Compounded versions through programs like Sunlight start at $159-$239 per month. The cost differential is the primary reason 100,000+ patients have enrolled in compounded GLP-1 programs - it makes access to this drug class practically achievable for people who can't get insurance coverage or afford brand pricing.

The clinical trial data is different. The 15-20% weight loss figures most often cited come from randomized controlled trials on brand-name FDA-approved versions (STEP trials for semaglutide, SURMOUNT trials for tirzepatide) - not from compounded versions specifically. Sunlight attributes its outcomes to its patient population's self-reported data, not to independent clinical trials on its specific formulations.

The insurance situation is different. Brand-name GLP-1 drugs may be covered by insurance for qualifying diagnoses. Compounded versions are not covered by insurance because compounded drugs fall outside formulary coverage by design. Sunlight's program is self-pay.

Buyer Takeaway: Sunlight states its program involves compounded semaglutide and tirzepatide. These compounded medications are not FDA-approved products and are not identical to branded versions in regulatory or quality-oversight terms. Buyers should ask what specific form of these compounds the dispensing pharmacy uses before enrolling. That distinction matters more in 2026 than it did in previous years, and it's the right framework for every buyer's evaluation.

How to Read the Patient Testimonials on Sunlight's Website

Important context before reading this section: Testimonials and outcome figures in Sunlight's materials are brand-reported and based on self-reported Sunlight user data. Individual results vary. These examples should not be interpreted as typical, guaranteed, or independently verified by this publication. Results depend on adherence to the program, provider guidance, and individual health factors.

Sourcing note: All patient names, testimonials, and outcome figures in this section are reproduced from Sunlight's publicly published website and marketing materials. This publication has not independently contacted, verified, or obtained consent from any individual named in these testimonials. Results are self-reported. Individual results vary.

Sunlight features patient testimonials prominently - both short one-line quotes from verified members and longer multi-sentence accounts attributed to named patients. Reading them correctly requires understanding how they're sourced.

Per Sunlight's own disclosures: "All claims and benefits referenced are based on self-reported data from Sunlight users following a treatment plan with compounded GLP-1 medications and medical consultations. Weight was reported at intake and every 3-4 weeks thereafter. Results may vary depending on adherence to the program and provider guidance."

The testimonials you see - patients reporting 22 lbs lost in two months, 27 lbs over three months, 41 lbs over five months - are self-reported by those specific individuals. They're not independently verified weight measurements. They're consistent with the range of clinical outcomes documented in FDA-approved GLP-1 trials, but they represent individual experiences under specific adherence conditions.

Customer ratings and testimonial data are brand-reported, not independently audited by this publication. Individual experiences vary. The factors that most influence outcomes with GLP-1 medications - in clinical trials and in telehealth programs - include starting weight, adherence to the program, dietary changes, exercise, and the presence of other health conditions.

Sunlight's testimonials don't carry fictional name disclosures, which means the names used (Amanda R., David M., Rachel T., James K., etc.) are presented as real patients. This publication has not independently contacted or verified these individuals.

Buyer Takeaway: The testimonials on Sunlight's site are brand-reported patient experiences, not independently verified outcomes. They're consistent with the clinical literature on GLP-1 drug class efficacy. The range of results (14 lbs to 41 lbs in the testimonials displayed) reflects the genuine variance in real-world outcomes.

The Clinical Evidence Behind GLP-1 Medications: What the Research Actually Shows

The drug class underlying Sunlight's medications - GLP-1 receptor agonists - has one of the strongest evidence bases in modern pharmacological weight management. This section covers what the peer-reviewed literature shows, so you're not relying only on a telehealth platform's marketing claims.

Semaglutide's clinical evidence: The STEP 1 trial, published in the New England Journal of Medicine (2021), enrolled 1,961 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition. Participants using once-weekly subcutaneous semaglutide 2.4 mg lost a mean of 14.9% of body weight versus 2.4% in the placebo group over 68 weeks. A subsequent trial in patients with type 2 diabetes showed somewhat lower but still clinically meaningful weight reduction. The FDA approved semaglutide (Wegovy) for chronic weight management in June 2021.

Tirzepatide's clinical evidence: The SURMOUNT-1 trial, published in the New England Journal of Medicine (2022), enrolled 2,539 adults with obesity who had at least one weight-related comorbidity excluding diabetes - a population chosen to test tirzepatide's weight management efficacy in a cleanly obesity-focused cohort rather than a diabetes-management context. Participants using tirzepatide 15 mg lost a mean of 22.5% of body weight versus 2.4% in the placebo group over 72 weeks - the largest weight reduction ever documented in a Phase 3 placebo-controlled trial for a pharmacological weight management agent at the time of publication, a figure that represented a significant outcome in the drug class at the time of publication. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023, making it the second GLP-1 receptor agonist approved specifically for weight management following semaglutide's 2021 Wegovy approval.

FDA-approved GLP-1 medications have substantial clinical trial evidence for chronic weight management in appropriate patients. That evidence applies to FDA-approved branded formulations, not to compounded versions, which haven't been separately evaluated in randomized controlled trials - the evidence base is for the FDA-approved branded formulations.

GLP-1 medications are prescription medications with real side effect profiles. The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain - typically dose-dependent and most prominent during dose escalation. More serious concerns flagged in FDA labeling for approved GLP-1 drugs include pancreatitis risk, thyroid C-cell tumor risk (observed in animal studies, clinical significance in humans unclear), and gallbladder disease. These are drug class effects relevant to both brand-name and compounded versions using the same class of medications, whether FDA-approved branded versions or compounded formulations.

Drug interactions are clinically relevant and represent one of the most important pre-enrollment conversations to have with a healthcare provider: GLP-1 agonists slow gastric emptying, which can affect the absorption timing and peak concentration of oral medications taken within the same window - a pharmacokinetic effect that's particularly important for drugs with narrow therapeutic windows like levothyroxine, warfarin, or certain oral contraceptives. Patients on insulin or other antidiabetic medications face a hypoglycemia risk when adding GLP-1 agonists because both mechanisms lower blood glucose, and dosing adjustments to existing medications may be required before starting a GLP-1 program. Any patient on antidiabetic medications, anticoagulants, or medications with narrow therapeutic windows should discuss these interactions with a prescribing clinician before starting.

Sunlight's clinical team performs a medical intake evaluation specifically to screen for contraindications. This is one of the legitimate advantages of a program with licensed prescribers over unregulated supplement alternatives.

Buyer Takeaway: The clinical evidence for GLP-1 receptor agonists is among the strongest in weight management pharmacology. The evidence is for FDA-approved branded formulations. The drug class side effect profile is real and requires qualified medical oversight - which Sunlight's model provides through licensed prescribers.

Who Qualifies for Sunlight GLP-1 - and Who Doesn't

Sunlight isn't a service you can simply pay for and receive medication. Eligibility is determined clinically by independent licensed providers. Here's what the intake process screens for, based on publicly available information:

The FDA-approved criteria for branded semaglutide and tirzepatide weight management indications include adults with initial BMI of 30 or higher (obesity), or adults with BMI of 27 or higher (overweight) plus at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. Sunlight's clinicians evaluate eligibility based on their independent medical judgment - the intake quiz collects health history that informs that evaluation.

Contraindications to GLP-1 medications that clinicians screen for include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), current or past pancreatitis, and severe gastrointestinal disease. Pregnancy is a contraindication. Patients with certain kidney conditions may require dose adjustment or may not be appropriate candidates.

If a clinician determines a telehealth consultation isn't appropriate for your particular health situation - or that your concerns require in-person care - you'll receive notification that you can't use the Services for that issue. This is a normal outcome from a medically responsible platform.

Patients with a prior GLP-1 prescription from another provider within the last two weeks can request to start at an equivalent dose rather than starting from the lowest titration point. This requires uploading the prior prescription to the patient portal and a clinician appointment to confirm the appropriate starting dose.

This service is for adults 18 years and older who can independently consent to the requested healthcare services in their jurisdiction.

Buyer Takeaway: GLP-1 medications aren't appropriate for everyone. Sunlight's clinical intake process - while conducted entirely online - is a real medical screening, not a rubber stamp. If you have significant comorbidities or a complicated medical history, discuss them fully during intake.

What This Guide Could Verify About Sunlight vs. What Requires Your Direct Confirmation

Here's what a review of Sunlight's publicly available materials can and can't confirm:

What could be verified:

• Legal operator identity (GLP-1, LLC d/b/a Sunlight.com, LLC), address, contact information - verified from Terms of Use

• Named medical team members and their stated credentials - verifiable through board certification registries

• Named pharmacy partners and their published addresses - verifiable through state pharmacy board registries

• Pricing ($159 semaglutide / $239 tirzepatide starting price) - confirmed on brand's FAQ

• Medications offered (compounded semaglutide and tirzepatide) - confirmed

• FDA non-approval of compounded GLP-1 products - confirmed by brand's own disclaimers and FDA policy

• Subscription and cancellation terms - confirmed from Terms of Use

• Refund policy (no refund once prescription written) - confirmed from Terms of Use

• LegitScript certification claim - brand states this; verifiable at legitscript.com

• FDA enforcement changes after shortage resolution - covered in the regulatory section of this article; verify current status with Sunlight before enrolling

What requires independent confirmation or can't be verified by this publication:

• 100,000+ patient count - brand-reported, not audited

• 98% patient success rate - brand-reported from self-reported data

• Specific patient outcomes cited in testimonials - self-reported individual experiences

• Current LegitScript certification status - check directly at legitscript.com

• Current pharmacy compounding compliance with 2026 FDA guidance - verify directly with Sunlight before enrolling

• Current pricing at time of enrollment - may change; confirm at checkout

Buyer Takeaway: The structural facts about Sunlight check out. The statistical claims are brand-reported and carry the standard caveats about self-reported data. The regulatory question most unique to 2026 - compounding compliance status - is the one to confirm directly before enrolling.

Sunlight GLP-1 vs. Competitors: Where It Stands in the 2026 Telehealth Market

The compounded GLP-1 telehealth market has contracted since its 2023-2024 peak. Several major 503B outsourcing facilities ceased production in early 2026 after the shortage pathways closed. The platforms still operating in May 2026 are the ones that built their infrastructure around patient-specific prescription models through state-licensed compounding pharmacies - which, per Sunlight's published Terms of Use, is the model its partner pharmacies operate under.

For a buyer evaluating Sunlight against alternatives in this category, the relevant comparison variables are: pricing structure, pharmacy transparency, prescriber credentials, and subscription flexibility. Sunlight's pricing ($159 for semaglutide, $239 for tirzepatide starting) is competitive with active alternatives in the market. Its pharmacy partners are named with addresses - not every competitor provides this level of sourcing transparency. Its medical team includes board-certified Obesity Medicine specialists, which is a more specific credential than general practice oversight. And its cancellation policy (email to cancel anytime) is as flexible as the category offers.

What Sunlight doesn't offer that some alternatives do: a satisfaction guarantee or outcome-based refund policy. Some competitors (outside this review's scope) have published outcome guarantees with refund provisions tied to weight loss thresholds. Sunlight's refund policy is explicitly limited - once a prescription is written, that order isn't refundable. Buyers who want outcome-based financial protection should ask Sunlight directly whether any such programs exist before enrolling, and should not assume they're included.

Buyer Takeaway: Sunlight's published materials reflect several of the transparency signals that distinguish established telehealth platforms in this category. Its transparent pricing, named pharmacy partners, credentialed medical team, and active LegitScript certification distinguish it from lower-quality entrants in the same category. The refund structure is more limited than some alternatives.

View the current Sunlight GLP-1 offer (official Sunlight page)

The Exact Timeline You're Working With When You Enroll - and the Moment That Changes Everything

If you're comparing GLP-1 programs right now, this is the section most guides skip. The timeline from "I'm interested" to "my prescription is written" is shorter than most buyers expect - and that sequence matters because of one specific term buried in Sunlight's published Terms of Use.

Here's what the enrollment sequence actually looks like:

• Day 0 - You submit the intake quiz. You answer the health history questions on Sunlight's site and enter payment information. At this point you haven't been charged a non-refundable amount yet if you're medically disqualified.

• Day 1 or shortly after - A licensed clinician reviews your intake. The clinician makes an independent prescribing decision. If they determine GLP-1 therapy is appropriate for you and write a prescription, this is the moment that changes your financial position. Per Sunlight's Terms of Use: once a prescription - first or refill - has been written and sent to the pharmacy, that order is not refundable.

• The refund cutoff is at prescription, not delivery. Not when your medication ships. Not when you receive it. When the prescription is written. If you change your mind the same day - after the Rx is issued - that billing cycle isn't reversible.

• Day 7 (business days) from approval - Your medication ships. Tracking information sent by email and text. Each shipment contains a 4-week supply.

• Weeks 2-4 - Titration begins. Starting dose phase. GI side effects, if they occur, are most common here. Clinical support is available at no additional charge for dosage questions or adjustments.

• Monthly thereafter - Auto-renewal activates. Your subscription renews automatically. Cancel anytime by emailing [email protected] before the next prescription cycle begins if you're not continuing.

Why does this timeline matter for your decision right now? Because the FDA's public comment period on its proposal to restrict large-scale compounded GLP-1 production closes at the end of June 2026. The regulatory picture may look different in July or August. Buyers who've already completed their medical evaluation and confirmed compounding availability with Sunlight are better positioned than buyers who start that process after a regulatory change takes effect.

That's not manufactured pressure. It's the actual sequence of events, laid out so you can make a deliberate decision rather than a reactive one.

Buyer Takeaway: The refund cliff activates when your prescription is written, not when your medication arrives. Map your own timeline before you submit the intake form. If you're uncertain about commitment, confirm the cancellation terms before your prescription is issued - not after.

How Sunlight's Subscription and Cancellation Terms Actually Work

This section exists because Sunlight's subscription terms contain one specific clause that catches more buyers off guard than anything else in the program - and it directly affects how you should time your enrollment decision relative to the FDA's June 2026 timeline.

Sunlight is a subscription service. Your payment method is charged automatically each month based on the cycle terms you agreed to during checkout. The subscription continues until you actively cancel it.

To cancel: email [email protected] with your name and the email address associated with your account. You can also contact your provider directly. Cancellation stops future charges. Your access continues through the end of your current billing period, per standard subscription practice.

The refund mechanics matter: if you're medically disqualified after starting the intake process, you receive a refund for unused months and the video consultation is free. But once a prescription - first order or any refill - has been written and sent to a pharmacy, that order is not refundable. This is stated explicitly in Sunlight's Terms of Use. The logic is that a prescription triggers pharmacy fulfillment costs that aren't recoverable.

If you decide GLP-1 treatment isn't right for you mid-program, cancel before your next prescription is written and dispatched. Timing matters here because of this refund cutoff.

Shipping and payment information can be updated by emailing [email protected]. Updates apply to the next order - they can't be applied to an order already in transit.

The subscription generates a 4-week supply per cycle. To keep your supply uninterrupted, Sunlight asks that you complete your refill form after your third weekly dose.

Buyer Takeaway: The subscription is easy to cancel via email. The refund cutoff - once a prescription is written, no refund - is the term that requires the most attention. If you're uncertain about continuing, cancel before the next fulfillment cycle begins.

What Happens to Compounded GLP-1 Programs After the FDA's June 2026 Comment Period Closes

This is the question most buyers in this category aren't asking yet - but should be. Here's a plain-English summary of what the FDA timeline means for compounded GLP-1 programs like Sunlight.

On April 30, 2026, the FDA published a formal proposal in the Federal Register (91 Fed. Reg. 23431) to exclude semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that 503B outsourcing facilities can use in compounding. The FDA's stated finding: there is no clinical need for large-scale outsourcing facilities to compound these medications when FDA-approved versions are commercially available. The public comment period closes at the end of June 2026.

Three outcomes are possible after comments close:

• FDA finalizes the exclusion (most likely per legal analysts). 503B outsourcing facilities - the large-scale compounding operations that produce the bulk of compounded GLP-1 supply - can no longer produce these medications. The patient-specific 503A pathway (which covers pharmacies filling individual prescriptions from licensed clinicians, like the model Sunlight uses through its partner pharmacies) continues under separate rules, but with significantly reduced supply volume and ongoing legal uncertainty about "essentially a copy" restrictions.

• FDA delays or modifies the proposal. The comment period generates significant pushback, and FDA issues a revised proposal or extends review. The market continues operating under the current framework while the regulatory process continues.

• FDA withdraws the proposal. Considered unlikely by most analysts given the shortage resolution and the FDA's stated position, but possible if legal challenges or congressional pressure intervenes.

What does this mean for someone considering Sunlight right now? If you're a clinical candidate for GLP-1 therapy and cost is a significant barrier to brand-name access, the current window - before a final FDA rule - is the clearest access window available. That's not manufactured urgency. It's the actual regulatory timeline, and understanding it helps you make a more deliberate decision.

Buyer Takeaway: The most important question to ask Sunlight before enrolling isn't "does the program work." It's "how is your program structured relative to the FDA's June 2026 timeline, and what happens to patient access if the exclusion is finalized?" Ask directly. Their answer - and their confidence in it - tells you a lot.

The Side Effects Buyers Should Know Before Starting

GLP-1 receptor agonists are prescription medications with documented side effects. This isn't a reason to avoid them if you're a good candidate - it's information that helps you make an informed decision and recognize what's expected versus what needs clinical attention.

The most commonly reported side effects in clinical trials for semaglutide and tirzepatide are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are typically most pronounced when starting the medication and during dose escalation phases. Per published clinical literature on GLP-1 receptor agonists, most patients report significant improvement as their body adjusts to the medication. The slow titration schedule used in approved protocols exists specifically to minimize these effects.

More serious effects that FDA labeling for approved GLP-1 drugs identifies as areas of monitoring include: pancreatitis (stop medication and contact your prescriber if you experience severe, persistent abdominal pain radiating to your back); thyroid C-cell tumors (observed in animal studies; human clinical significance is not established but patients with personal or family history of medullary thyroid carcinoma or MEN 2 are contraindicated); gallbladder disease; hypoglycemia risk particularly in patients on concurrent insulin or sulfonylureas; and acute kidney injury, typically secondary to dehydration from GI side effects.

Depression and mood changes are also listed as potential side effects. Per Sunlight's own published website, these medications "can cause serious side effects, including thyroid c-cell tumors and depression." Patients with a personal history of depression or mood disorders should raise this explicitly with the prescribing clinician during the intake evaluation.

These are drug class effects. They apply to compounded semaglutide and tirzepatide in the same way they apply to brand-name versions because the active molecules are the same. Sunlight's clinical team conducts a medical intake evaluation that screens for contraindications - which is one of the reasons this type of program is preferable to seeking these medications through non-medical channels.

Ongoing clinical oversight is included in Sunlight's subscription. If you experience unexpected or concerning side effects, the clinical team can be reached through the platform at no additional cost.

Buyer Takeaway: GI side effects are common, especially early in treatment, and typically manageable. More serious effects are less common but require awareness. The included clinical support is a genuine safety resource, not just a marketing feature.

Frequently Asked Questions About Sunlight GLP-1

Is Sunlight GLP-1 FDA-approved?

No. Sunlight is a telehealth platform that facilitates access to compounded GLP-1 medications - specifically compounded semaglutide and tirzepatide. Compounded medications are prepared by state-licensed compounding pharmacies filling patient-specific prescriptions. The FDA has not approved compounded medications for safety, efficacy, or quality. This distinction is stated explicitly in Sunlight's own website disclaimers and Terms of Use. The FDA-approved brand-name medications in these same drug classes are Ozempic and Wegovy (containing semaglutide, manufactured by Novo Nordisk) and Mounjaro and Zepbound (containing tirzepatide, manufactured by Eli Lilly) - all FDA-reviewed for safety, efficacy, and quality, which compounded versions are not.

Is Sunlight GLP-1 legal in 2026?

As of May 2026, compounded semaglutide and tirzepatide are available through patient-specific prescription models at telehealth platforms including Sunlight. However, the legal framework is under active change. On April 30, 2026, the FDA announced - per fda.gov and the Federal Register (91 Fed. Reg. 23431) - a formal proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list. The public comment period closes at the end of June 2026. If finalized, large-scale bulk compounding ends entirely. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in October 2024. The FDA has proposed further restricting large-scale outsourcing compounding of these drug classes. Sunlight's Terms of Use identify its pharmacy partners as state-licensed compounding pharmacies that fill patient-specific prescriptions from licensed clinicians - a model distinct from large-scale 503B outsourcing facilities, which is the compounding category the FDA's ongoing enforcement review of large-scale outsourcing compounding targets. The 503A patient-specific compounding pathway remains in operation, though it carries ongoing legal considerations given the shortage resolution. Buyers should verify current compounding status directly with Sunlight before enrolling. This article doesn't constitute legal advice.

How much does Sunlight GLP-1 cost per month?

Sunlight's brand-published starting prices are $159 per month for compounded semaglutide and $239 per month for compounded tirzepatide (first month pricing, per brand statements). These flat monthly rates include the compounded prescription, unlimited telehealth visits with licensed clinicians, and free 2-day shipping. No insurance is required. Sunlight describes its GLP-1 plans as self-pay with flat monthly pricing; HSA and FSA payments are accepted. Buyers should confirm payment options at checkout. Prices may change - confirm at checkout before completing your purchase. Taxes are calculated separately at checkout.

What are the Sunlight GLP-1 side effects?

The most commonly reported side effects for GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These are most prominent when starting the medication and during dose escalation, and typically improve as the body adjusts. More serious effects that FDA labeling flags for this drug class include pancreatitis risk, thyroid C-cell changes (observed in animal studies), gallbladder disease, and hypoglycemia risk in patients combining GLP-1 agonists with insulin or sulfonylureas. Sunlight's clinical team conducts medical intake screening and provides ongoing support - contact the clinical team through the platform if you experience unexpected symptoms.

Can I cancel Sunlight GLP-1 anytime?

Yes. Per Sunlight's Terms of Use, you can cancel at any time by emailing [email protected] with your name and associated email address. Your access continues through the end of your current billing period after cancellation. The critical term to understand: once a prescription has been written and sent to the pharmacy for fulfillment, that order is not refundable. Cancel before your next prescribing cycle if you don't want to continue, and do so before the prescription is issued.

Does Sunlight GLP-1 require insurance?

No. Sunlight's program is self-pay only and does not require or accept insurance. Per brand statements, all plans include flat monthly pricing covering the prescription, unlimited telehealth visits, and free shipping. HSA and FSA payments are accepted. Compounded GLP-1 medications are not covered by insurance because compounded drugs fall outside standard formulary coverage. If you have employer-sponsored or marketplace insurance that covers branded GLP-1 medications, you may want to compare total out-of-pocket costs between the brand-name covered option and Sunlight's self-pay compounded option before choosing.

How is Sunlight GLP-1 different from Ozempic or Wegovy?

Sunlight states its program involves compounded semaglutide, produced by licensed compounding pharmacies against patient-specific prescriptions. Compounded semaglutide is not an FDA-approved product and isn't identical to or interchangeable with branded medications in regulatory terms. An important caveat: the FDA has warned that some compounded semaglutide products use semaglutide salt forms - semaglutide sodium or semaglutide acetate - that are chemically different from the active ingredient in FDA-approved Ozempic and Wegovy. Ask Sunlight to confirm the specific form used before your prescription is written. Ozempic and Wegovy are brand-name FDA-approved products manufactured by Novo Nordisk under FDA cGMP standards, reviewed for safety, efficacy, and quality through the full approval process. Compounded semaglutide hasn't undergone that premarket review. The clinical trial evidence most often cited for 15-20% weight reduction comes from STEP program trials on FDA-approved branded semaglutide - not from compounded formulations. The primary practical consideration for many buyers is cost: brand-name GLP-1 drugs can exceed $1,000 per month without insurance; per Sunlight's published FAQ, compounded semaglutide starts at $159 per month.

What do Sunlight GLP-1 reviews say about results?

Patient testimonials on Sunlight's website describe weight loss experiences ranging from approximately 14 lbs in six weeks to 41 lbs over five months. Sunlight's website reports 100,000+ patients served and cites a 98% patient success rate from its own self-reported data. Per Sunlight's own disclaimer, results are based on self-reported patient data and may vary depending on adherence to the program and provider guidance. Individual outcomes with GLP-1 medications vary based on starting weight, adherence, dietary habits, exercise, and clinical factors. Customer ratings and data are brand-reported and not independently audited by this publication.

How quickly does Sunlight ship medication after approval?

Per Sunlight's FAQ, once approved, prescriptions are shipped within 7 business days. Sunlight states free 2-day shipping on the lander. You'll receive tracking information via email and text as soon as your order ships. Each shipment contains a 4-week supply of medication. To maintain an uninterrupted supply, complete your refill form after your third weekly dose of the current supply.

What happens if I'm medically disqualified by Sunlight?

Per Sunlight's Terms of Use, if you're medically disqualified, you'll receive a refund for any unused months on your plan and your video consultation will be free. This is the exception to the general no-refund policy. You'll receive notification through the platform that you're unable to use the Services for your submitted health concern, and you'll need to seek care through alternative providers. This outcome reflects a medically responsible platform appropriately excluding candidates who aren't suitable for GLP-1 treatment.

Who are the licensed clinicians at Sunlight?

Sunlight's named medical team includes Angela Tran, D.O. (Chief Medical Advisor, double-board-certified in Obesity Medicine and Internal Medicine, 10+ years of clinical experience), Ilya Rabkin, MD, MBA, FAAFP (board-certified Family Medicine physician, recognized by Gold Humanism Honor Society), and Amanda Simone-Belin, MD (board-certified Internal Medicine physician specializing in medical weight loss). Sunlight's healthcare services are delivered through affiliated Medical Groups including OpenLoop Health and JMP Medical, which employ or contract with the licensed clinicians who provide prescriptions.

Can I transfer my existing GLP-1 prescription to Sunlight?

Per Sunlight's FAQ, if you've been prescribed a GLP-1 medication by another provider within the last two weeks, Sunlight's clinicians may approve you to start at an equivalent dose rather than the lowest titration. You'd upload your prior prescription to the patient portal and schedule a clinician appointment to confirm the appropriate starting dose. This isn't a transfer of your existing prescription - it's a new prescription from Sunlight's affiliated clinicians based on your documented treatment history.

Is Sunlight available in my state?

Per brand statements, Sunlight currently offers services in all 50 states plus Washington D.C. State availability is subject to change based on licensing and regulatory requirements. Some services may not be available in all states. Confirm availability for your specific state at Sunlight.com before starting the intake process. Clinical eligibility requirements may also vary by state due to local medical licensing and prescribing laws.

What are the qualifications to use Sunlight GLP-1?

The platform is available to adults 18 years of age or older who can independently consent to healthcare services in their jurisdiction. Clinical eligibility - meaning whether you'll actually receive a prescription - is determined by the licensed clinician reviewing your health intake. The FDA-approved indications for branded GLP-1 weight management drugs include adults with BMI of 30 or higher, or adults with BMI of 27 or higher plus a weight-related condition (type 2 diabetes, hypertension, high cholesterol). Sunlight's affiliated clinicians evaluate individual eligibility based on your health history.

What compounding pharmacies does Sunlight use?

Sunlight's Terms of Use list four pharmacy partners: RedRock Pharmacy (1240 E 100 S #220, St. George, UT 84790); Health Warehouse (7107 Industrial Rd., Florence, KY 41042); Precision Compounding Pharmacy (2657 Merrick Road, Bellmore, NY 11710); and Triad Rx (26258 Pollard Road, Daphne, AL 36526). These are state-licensed compounding pharmacies. You can verify pharmacy licenses through state pharmacy board public registries. The specific pharmacy that fills your prescription may vary by location and availability.

What is the semaglutide salt form issue, and does it affect Sunlight?

The FDA has specifically warned that some compounded semaglutide products have used semaglutide salt forms - such as semaglutide sodium or semaglutide acetate - rather than the base form of semaglutide used in FDA-approved medications like Wegovy and Ozempic. These salt forms are chemically distinct from the active ingredient used in FDA-approved semaglutide products. They haven't been evaluated by the FDA for safety or efficacy. The FDA has received adverse event reports tied to compounded GLP-1 products, including some involving dosing errors and product quality concerns. Ask this before you hand over payment information to any compounded GLP-1 program: what specific form of the active ingredient does the dispensing pharmacy use, and can they confirm it in writing? This publication has not independently verified the specific forms used by Sunlight's pharmacy partners. Ask directly at [email protected] or 1-877-378-7008 before completing your intake.

Is there a Sunlight GLP-1 oral option?

Sunlight's lander mentions "injections and oral options available." This publication has not independently confirmed the specific oral formulations currently offered, and oral availability may depend on your clinical evaluation and prescribing clinician's judgment. Ask Sunlight directly at [email protected] or 1-877-378-7008 about current oral options before assuming they're available for your situation.

9 Things to Verify Before You Enroll in Sunlight - Run This Checklist Before You Hit Submit

You're probably 5-10 minutes from submitting Sunlight's intake form. Before you do, run through these nine items. Each one addresses a specific risk point that isn't obvious from the landing page - and some of them have real financial or medical consequences if you skip them.

• 1. Confirm current pricing at checkout. The $159 semaglutide / $239 tirzepatide starting prices are brand-published as of May 2026. Confirm your exact total - including any taxes calculated at checkout - before payment. Prices in telehealth can change without notice. Why now: pricing is the single most frequently updated element on programs like this.

• 2. Ask Sunlight to confirm current compounding compliance status. Contact [email protected] or call 1-877-378-7008. Ask one direct question: "Is your program currently operating within FDA enforcement guidance for compounded GLP-1 medications?" Get a written answer before enrolling. Why now: the FDA comment deadline is weeks away. Availability may change.

• 3. Ask what form of semaglutide or tirzepatide the pharmacy uses. The FDA has warned that some compounded products use salt forms - semaglutide sodium or semaglutide acetate - that are chemically distinct from the base compound in FDA-approved products. Ask Sunlight to confirm the specific form used by your assigned pharmacy before your prescription is written. Why now: this is the question 90% of buyers never ask.

• 4. Read the refund policy before the prescription is written. Per Sunlight's Terms: once a prescription is written and sent to the pharmacy, that order is not refundable. The cutoff is at prescription, not delivery. If you have doubts, raise them before the clinician issues the Rx. Why now: there is no reversal after this point.

• 5. Confirm your state is currently served. Sunlight states it operates in all 50 states plus D.C., but state-level telehealth licensing requirements can change. Confirm availability for your specific state at Sunlight.com before starting intake. Why now: state availability can shift without advance notice to buyers.

• 6. Review your current medications for GLP-1 interactions. GLP-1 agonists slow gastric emptying, which affects absorption timing for oral medications. Hypoglycemia risk is real if you're on insulin or sulfonylureas. Bring a complete medication list to your clinical intake - not a partial one. Why now: drug interactions are a leading cause of adverse events in this category.

• 7. Verify LegitScript certification status independently. Sunlight claims LegitScript certification. Verify it directly at legitscript.com before you enroll - don't take the website's word for it. Why now: certification status can lapse or change.

• 8. Set a cancellation reminder for before your next billing cycle. If you're uncertain about long-term commitment, put a calendar reminder 3 weeks after enrollment to evaluate whether you want to continue. Cancel via email ([email protected]) before the next prescription is issued if you're stopping. Why now: the easiest cancellation is the one you plan for before you need it.

• 9. Ask about the specific oral formulation if you want oral dosing. Sunlight's lander mentions oral options, but oral availability isn't confirmed for all patients or locations. Ask directly at [email protected] before assuming it's available for your situation. Why now: oral GLP-1 availability in compounded form is more limited than injectable.

Buyer Takeaway: Sunlight's published materials reflect several transparency signals in a category with real regulatory complexity. The verification steps above take less than an hour and give you a significantly more informed starting point than most buyers have when they enroll.

What Happens After Your First Month on Sunlight

The first month of GLP-1 therapy looks different from month two and beyond - and knowing what to expect helps you evaluate whether the program is working as it should versus whether something needs clinical attention.

The first few weeks typically involve starting at the lowest titration dose. GLP-1 medications work best when doses are increased gradually - this is the standard protocol for both brand-name and compounded versions. Nausea and gastrointestinal discomfort, when they occur, are most commonly reported during this early escalation phase. Starting slowly minimizes these effects without compromising the eventual therapeutic benefit.

By weeks three and four, most patients who respond well to GLP-1 medication begin to notice reduced appetite and changes in food cravings. The mechanism is central - GLP-1 receptor agonists act on appetite-regulating centers in the brain in addition to slowing gastric emptying. Some patients describe the experience as feeling genuinely full on smaller amounts of food, rather than feeling forced to restrict.

After month one, you'll receive a refill by completing Sunlight's refill form after your third weekly dose of the current supply. This timing ensures uninterrupted access. If you need a dosage adjustment before refill - because you're tolerating the current dose well and your clinician thinks escalation is appropriate, or because you're experiencing side effects - that conversation happens through the platform at no additional cost.

Sustainable GLP-1 outcomes in clinical trials were observed over 68-72 weeks, not 4-8 weeks. Patients who stop the medication typically see weight return over time, which is consistent with the clinical understanding that these medications address biological drivers of appetite rather than "curing" the underlying condition. Long-term continuation decisions are individual - that's a conversation for you and the prescribing clinician.

Buyer Takeaway: Month one is titration and adjustment. The clinical benefit builds over months two through six and beyond. Going in with realistic expectations about timeline - not a 30-day transformation promise - sets you up for an honest evaluation of whether the program is right for you.

Contact Information and How to Reach Sunlight's Support Team

Direct contact with Sunlight is straightforward. The brand publishes complete contact information that this article can confirm from the official Terms of Use and website:

• General support email: [email protected]

• Patient support email: [email protected] (use for cancellations and account matters)

• Phone: 1-877-378-7008

• Mailing address: 11335 NE 122nd Way, Suite 105, Kirkland, WA 98034

• Privacy officer address: 317 6th Ave. Ste. 400, Des Moines, IA 50309 (for HIPAA-related written communications)

The patient support team handles cancellations, shipping/payment updates, and account questions. Clinical questions and dose adjustment requests go through the in-platform care team available in your patient portal.

View the current Sunlight GLP-1 offer (official Sunlight page)

Final Buyer Notes: What to Take Away From This Guide on Sunlight GLP-1

As of May 2026, here's what the transparency check on Sunlight's published materials actually turns up: a named legal operator with a verifiable address, published contact information, active telehealth consent terms updated in 2026, named clinicians with stated credentials, and listed pharmacy partners with published addresses and phone numbers. For a buyer who is a clinical candidate for GLP-1 medication and who can't access or afford brand-name coverage, it offers access to compounded semaglutide and tirzepatide at dramatically lower cost, with licensed clinical oversight included in the subscription price. Compounded versions are not FDA-approved products, and buyers should not assume they are identical, interchangeable, or equivalent to FDA-approved branded medications.

The case for considering it is straightforward: the underlying drug class (GLP-1 receptor agonists) has the strongest weight management evidence base in clinical pharmacology, supported by multiple large-scale randomized controlled trials showing 15-22% weight reduction in study populations over 68-72 weeks. The program includes licensed prescribers, unlimited clinical support, named pharmacy partners with verifiable addresses, and an all-inclusive pricing structure that's cleaner than most alternatives in this category - which matters when you're committing to a monthly subscription with real healthcare stakes involved.

The case for proceeding cautiously is equally straightforward: compounded GLP-1 medications are in a period of active regulatory transition that buyers in 2024 and early 2025 didn't have to navigate, and that transition isn't finished yet. The FDA shortage pathway that built this entire industry is closed. The FDA has taken formal steps to restrict or eliminate large-scale outsourcing compounding of these drug classes, and the regulatory picture remains in active development at the time this article was written. The 503A patient-specific compounding pathway - which covers pharmacies filling individual prescriptions from licensed clinicians - remains in operation under current law, though it carries ongoing legal uncertainty that any responsible evaluation of this category needs to flag clearly. And the brand-name alternatives - while dramatically more expensive without insurance - now have stable supply for the first time since 2022, which means the comparison calculus has shifted.

What this means for you as a buyer: Sunlight may be worth further review if you're a clinical candidate and the cost of brand-name GLP-1 drugs is prohibitive - which for most people without insurance coverage, it still is. The FDA's public comment period on the proposal to end large-scale compounded GLP-1 production closes at the end of June 2026. If that proposal is finalized - which most healthcare law analysts expect by late summer 2026 - the compounded GLP-1 market changes significantly. That's not a reason to panic or rush into an unevaluated decision. It's a reason to complete your evaluation now rather than defer it. Have a direct conversation with Sunlight's patient support team about current compounding status before you enroll. That's information that could change between when this article was written and when you're reading it - and you want the current answer, not the one we captured in May 2026. And it's worth understanding the refund policy clearly - because the moment your prescription is written, that billing cycle isn't reversible, and that's a feature of the service you should enter with full awareness.

None of this is a reason to avoid GLP-1 treatment if you're an appropriate candidate. It's a reason to enter the process informed rather than on the momentum of a landing page.

View the current Sunlight GLP-1 offer (official Sunlight page)

Disclaimer: Statements made in this article have not been evaluated by the Food and Drug Administration. This content is not intended to diagnose, treat, cure, or prevent any disease. GLP-1 medications - including both FDA-approved branded versions and compounded versions - are prescription medications that require evaluation by a licensed clinician. This article is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any prescription medication or weight management program.

FDA Compounded Medication Disclosure: Compounded medications, including compounded semaglutide and tirzepatide, have not been evaluated by the FDA for safety, effectiveness, or quality. They are not FDA-approved. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in October 2024. After the FDA determined that the semaglutide shortage (February 2025) and tirzepatide shortage (October 2024) were resolved, enforcement of compounding restrictions changed significantly. The FDA has continued to issue guidance on compounded GLP-1 medications and is reviewing further restrictions on large-scale outsourcing compounding of these drugs. Buyers should confirm current compounding compliance status with Sunlight before enrolling.

Affiliate Disclosure: This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products or services. Disclosure is provided in accordance with FTC 16 CFR Part 255.

Testimonial Disclaimer: Customer ratings and testimonials are brand-reported, not independently audited by this publication. All testimonial claims are based on self-reported data from Sunlight users. Individual experiences vary. Results depend on adherence to the program, provider guidance, and individual health factors.

Trademark Notice. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Victoza® and Saxenda® are registered trademarks of Novo Nordisk A/S. These marks are referenced in this article for identification and nominative comparison purposes only. This article is not affiliated with, sponsored by, or endorsed by Novo Nordisk, Eli Lilly, or any of their affiliated entities. Use of these marks does not imply any commercial relationship between this publication and the trademark owners.

Material Limitations of This Review. This review is based exclusively on publicly available materials, including the official Sunlight.com website, the brand's published Terms of Use, Telehealth Consent Form, and category-level regulatory guidance on compounded GLP-1 medications. This publication has not received compensated access to the platform, has not been a patient in the program, has not interviewed Sunlight personnel, and has not conducted laboratory or performance testing of any compounded medication provided through Sunlight. Claims described as "according to the brand" or "per brand statements" reflect what Sunlight has publicly stated and have not been independently substantiated by this publication. Buyers are encouraged to verify any claim that materially affects their enrollment decision by contacting Sunlight directly at [email protected] or 1-877-378-7008.

Third-Party Consumer Feedback Platforms. This article references brand-reported patient testimonials and the existence of third-party review data in general terms only. This publication does not endorse, vouch for, audit, or accept responsibility for the accuracy, completeness, or fairness of customer reviews posted on any third-party platform. Buyers consulting third-party reviews are encouraged to evaluate them critically, look for verified-purchase indicators where available, and weigh reviewer-specific context against their own situation.

Forward-Looking Statements and Article Accuracy. This article reflects information available as of May 2026 and was prepared using reasonable care to be accurate and useful at the time of publication. Product specifications, pricing, program structure, shipping policies, refund policies, contact information, regulatory status, and customer data may change after publication without notice. Statements describing expected buyer outcomes, performance expectations, or category regulatory trends are educational forward-looking observations, not guarantees. No representation is made that the information will remain accurate in the future, and no warranty of merchantability, fitness for a particular purpose, or non-infringement is provided in connection with the editorial content of this article. Readers should rely on the official Sunlight.com website as the authoritative source for current program information prior to any enrollment decision.

Reasonable Consumer Standard. This article is written for a general adult consumer audience and intends statements to be interpreted as a reasonable consumer would interpret them in context. Where a statement could otherwise be read as a verified fact, attribution language such as "according to the brand," "brand-stated," "per brand statements," or "per Sunlight's FAQ" identifies it as a brand claim that has not been independently verified by this publication. Promotional statistics and outcome claims appearing on Sunlight's website - including, without limitation, "100,000+ happy customers," "98% patient success rate," "15-20% body weight loss," "9/10 patients kept it off," and similar figures - are explicitly identified in this article as brand-reported, self-reported data metrics and are not represented as independently verified or laboratory-confirmed results by this publication.

Geographic and Jurisdiction Notice. This article is published for a general US adult audience. Healthcare regulations, prescription requirements, telehealth laws, and consumer protection rights vary by state and jurisdiction. GLP-1 telehealth services are subject to state medical licensing requirements. Some services may not be available in all states. California residents have additional consumer protection rights under California law and additional disclosure rights as noted in Sunlight's Telehealth Consent Form. EU and international readers: this content reflects US regulatory frameworks; applicable regulations in your jurisdiction may differ materially. Consult local legal counsel for jurisdiction-specific questions.

California Consumer Notice. California residents purchasing from or considering purchasing from online sellers should be aware that certain substances, materials, and products can expose individuals to chemicals including those known to the State of California to cause cancer, birth defects, or other reproductive harm. For compounded prescription medications, consult with your licensed clinician and dispensing pharmacy regarding any California-specific disclosure requirements. This notice is provided for informational purposes as this service ships to California residents. The Open Payments database for California physician payment transparency can be found at openpaymentsdata.cms.gov.

No Affiliation or Endorsement. This publication is not affiliated with, operated by, endorsed by, or sponsored by Sunlight.com, GLP-1, LLC, OpenLoop Health, JMP Medical, or any affiliated Medical Group or pharmacy. This is an independent editorial review. The presence of an affiliate link in this article does not constitute an official partnership, joint venture, or employment relationship between this publication and Sunlight.

AI Content Disclosure. This content was prepared with editorial and AI-assisted drafting support. All claims were reviewed against available brand, regulatory, and legal source materials before publication.

SOURCE: Sunlight

Source: Sunlight